Skip to main content
Equibles
HUMA logo

HUMA · Humacyte, Inc.

Track HUMA — free
$0.67 +0.01 (+2.26%) At close · Jul 21
Going-concern doubt — flagged May 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company will not have sufficient liquidity to fund its operations beyond one year from the issuance of these condensed consolidated financial statements if the Company is unable to generate sufficient cash flows from commercial sales on a timely basis and/or obtain additional capital. These factors raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed May 13, 2026
Market Cap
$148.93M
Shares
222.02M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.67 Open$0.64 Day$0.64–0.71 52W$0.55–2.84 Avg vol 30d14.4M Short int31.6M · 14.2% float · 1.3d Short vol48% Last earningsMar 31, 2026 DataDec 2020–Jul 2026 Filing10-Q · May 13

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 13, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 17.1 · elevated Equity put/call 0.65
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −39%
      below
      Price vs 50-day avg −30%
      below
      RSI (14) 38
      neutral
      MACD trend Positive
      52-week position 5%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −20%
      trailing
      6-month return −35%
      trailing
      YTD return −30%
      this year
      Relative strength −42%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      24 of 160 funds reported for Jun 30 · net +114.5K sh shares · +5 new
      Insider flow Distributing
      Net -$22.5K over 90 days · 50% sells
      Short interest Falling
      14.23% of float · ▼ -13.9% MoM · 1.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      160 holders — mid 3-yr range
      Squeeze score 58
      elevated · 0–100
      Fundamentals
      Strong
      EPS growth +79%
      Y/Y
      Free cash flow $-105.9M
      Balance sheet $15.1M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 114%
      annualized · 1-yr
      Max drawdown −79%
      past year
      ATR 12.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 3 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −39% Bearish
      Price vs 50-day avg
      −30% Bearish
      RSI (14)
      38 Neutral
      MACD trend
      Positive Bullish
      52-week position
      5% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      24 of 160 funds reported for Jun 30 · net +114.5K sh shares · +5 new
      Insider flow Distributing
      Net -$22.5K over 90 days · 50% sells
      Short interest Falling
      14.23% of float · ▼ -13.9% MoM · 1.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      160 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $1 Now $1 · 5% 52-wk high $3
      vs 200-day avg -39% vs 50-day avg -30%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      estimated savings for remainder of 2026 (net of severance and benefits) $14.3M remainder of FY2026 call —
      estimated severance and termination benefits (restructuring) $0.8M Q2 2026 (expected) call —
      patients enrolled in V012 Phase III clinical trial 120 Q1 FY2026 update (to date) call —
      Symvess commercial sales (units) 29 first quarter call —
      workforce reduction (employees) 45 May 2026 call —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      HUMA
      Humacyte, Inc.
      this stock
      		$148.93M -30.2% — — 14.2%
      ONC
      BeOne Medicines Ltd.
      		 $460.58B +4.9% +22179.2% 937.3 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $122.33B +6.3% +46.2% 28.6 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $70.79B -12.4% +20.8% 16.5 3.3%
      ARGX
      Argenx SE
      		 $54.72B +4.0% — — 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      164
      % held
      26.8%
      Reported
      24 of 160
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      103
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      31.6M
      Days to cover
      1.3d
      Change
      -5.1M sh
      View
      Short Volume
      Short vol %
      48%
      As of
      Jul 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      49.0K
      Value
      $39.2K
      As of
      Jun 30, 2026
      View
      Off-Exchange
      Off-exchange %
      69.5%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$22.5K
      Buyers / Sellers
      2 / 2
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Thomas H Tuberville
      Amount
      $15.0K–$50.0K
      Traded
      May 3, 2024
      View
      Financials
      Financials
      Revenue (FY)
      $2.0M
      Net income (FY)
      $-40.8M
      EPS diluted
      $-0.26
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 11, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $41.1K
      Shares
      45.9K
      Filed
      May 18, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Mar 31, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      HUMA -5.1% -20.1% -34.9% -14.0% -30.2%
      SPY -0.5% +0.5% +7.6% +0.2% +9.7%
      vs SPY -4.7% -20.6% -42.5% -14.2% -39.9%
      Key facts CIK 1818382 CUSIP 44486Q103 13F (30d) 24 filings 24 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)